This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) is considering hair loss as one possible area for future expansion as it looks beyond its core obesity and diabetes franchises, with the idea emerging alongside a broader strategy reset. Chief Scientific Officer Martin Lange said the company could apply its drug-development expertise to the hair-loss field, although it is not currently among the conditions targeted for mid-stage trials. Novo has also said some consumer-focused programs could reach the market before the end of the decade. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator.NVO GF Value chart The Danish drugmaker's Sept.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.